Back to All Combinations

APC + KRAS + TP53

Intermediate Prognosis
20.00% Prevalence Level 2B TP53 Combinations
Genes Involved
APC KRAS TP53
Treatment Implications

Classic Vogelstein adenoma-carcinoma sequence.

Recommended Treatments
FOLFOX + Bevacizumab
FOLFIRI + Bevacizumab
Treatments to Avoid
Anti-EGFR
Study References

Vogelstein model

Key Statistics
20.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Canonical CRC development pathway.
Information

Category: TP53 Combinations

Evidence Level: Level 2B

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.